While critical for efficient and successful drug development, dose selection in early phase oncology trials is very challenging. Phase 1 oncology trials have typically been designed to identify the highest, safe dose of a new drug – the maximum tolerated dose (MTD) from the responses of a small, often heterogeneous, cohort of cancer patients. The MTD identified is then used in either a phase 2 trial or an expansion of the phase 1 study to obtain preliminary efficacy data..
While phase 1 trials have historically identified the MTD using a simple, rule-based design, such as the classical “3+3” method, regulators are starting to encourage model-based and model-assisted designs, which can make MTD estimation more accurate and drug efficacy assessment more reliable in early phase oncology studies. However, selecting and implementing the optimal model-based or model-assisted design can be daunting, and requires statistical expertise. Many designs exist and vary in their approach to balancing participant safety, accurate dose selection and simplicity.
ICON has demonstrated expertise and ability to design smarter innovative early phase oncology studies through model simulation, consultation and support. For example, ICON successfully identified, modified and implemented two Bayesian model-assisted designs in a two-part, first-in-human trial of a tri-specific antibody, which targeted multiple tumour types. The first part of the phase 1 trial aimed to assess drug safety and toxicity, while subsequent dose-expansion cohorts obtained preliminary efficacy data.
Implementing BOIN in a dose-escalation study to assess drug safety and toxicity
The model-assisted BOIN design was selected for an open-label, dose-escalation study of the tri-specific antibody because initial information regarding the expected dose-toxicity curve was limited, and BOIN
-
is theoretically optimal at MTD selection
- requires less statistical processing than model-based designs
- is intuitive to investigators
Subsequent simulation assessment of the study design’s operating characteristics confirmed that the design would select the true MTD and allocate the most patients to dose levels nearest to the target toxicity rate.
After initiation of the trial, it became clear that the drug was benign, and that toxicity did not increase monotonically with dose, as is traditionally assumed. Through additional simulation, ICON identified and implemented modifications to the BOIN design that maximised safety and pharmacodynamic information without increasing patient numbers, costs or study timelines.
Implementing BOP2 in a dose-expansion cohort to obtain preliminary efficacy data
The BOP2 design was selected for dose-expansion cohorts of the phase 1 trial because it
- requires few patients
- can handle simple and complicated endpoints under a unified Bayesian framework
Since the dose-escalation study established that the drug was benign, the initial design was amended to better assess clinical activity. As with BOIN, the design's operating characteristics and analysis method for the different approaches were verified through simulation.
Smarter early phase trial designs continue to evolve
Although Bayesian-based BOIN and BOP2 methods are superior to rule-based designs, alternative strategies may be optimal based on a drug’s characteristics and the study objectives. For example, if a drug is initially known to be benign, then an alternative, more efficient design to explore safety and efficacy simultaneously, such as the BOIN-ET or BOIN 12 design, may be considered. These designs allow efficacy and safety to be studied simultaneously.
Historically, oncology drugs have been developed based on the belief that “more is better”. However, this presumption is not true for modern targeted drugs such as monoclonal antibodies. Subsequently Project Optimus, a cross industry/regulatory initiative, is encouraging sponsors to identify the optimal biological dose (OBD). Consequently, study designs such as the BOIN-ET and BOIN 12 are likely to become even more common in the future.
Studies that want to test a drug in patients with different types of cancer may also benefit from deploying basket designs within a master protocol when obtaining preliminary efficacy data. Extracting information across cohorts can also improve the efficiency of the statistical analysis using a Bayesian framework. As oncology therapeutics and early phase design models evolve, sponsors will benefit from working with a partner experienced in innovative adaptive designs for phase 1 and 2 oncology trials.
To learn more, please view our case study: Improving early phase oncology clinical trial design using Bayesian based BOIN and BOP2 designs or contact us to speak with our experts.
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel